Background: Enfuvirtide (T-20), a C-terminal heptad repeat (C-HR)-derived peptide of HIV-1 glycoprotein, gp41, effectively suppresses HIV-1 replication through a putative mechanism that involves it acting as a decoy and binding to the N-terminal heptad repeat (N-HR) of the virus. In this study, we address whether the anti-HIV-1 activity of T-20 is antagonized by a variety of N-HR-derived peptides. Methods: Multinuclear activation of galactosidase indicator assays were used to evaluate T-20 activity in the presence of N-HR-derived peptides. The gp41-derived peptides were chemically synthesized. Results: We demonstrate additive anti-HIV activity when T-20 is used in combination with N-HR-derived peptides that do not have a putative binding region for the tryptophan-rich domain in T-20. The presence of a deep pocket-forming region in the N-HR-derived peptides enhanced their anti-HIV-1 activity, but had little effect on the activity of T-20. Conclusions: These results indicate that T-20-based antiviral therapies can be combined with N-HR-derived peptides.
Two envelope glycoproteins of HIV-1, gp120 and gp41, play an important role in HIV-1 entry into the host cells. The surface subunit gp120 recognizes receptors CD4 and CXCR4/CCR5, which are expressed on the target cell surface. After binding to these receptors, the transmembrane subunit gp41 ( Figure 1A ) mediates fusion of HIV-1 to the host cells. Viral membrane-anchored gp41 forms a 6-helix bundle composed of an α-helical trimer of an N-terminal heptad repeat (N-HR) with three C-terminal heptad repeats (C-HR) folded onto the N-HR in an anti-parallel orientation [1] . Formation of the 6-helix bundle enables fusion between the viral and the host cell membranes. Therefore, peptides derived from either HIV-1 gp41 N-or C-HR sequences have been thought to inhibit HIV-1 fusion by preventing formation of the 6-helix bundle, and by acting as a dominant negative or a decoy [2, 3] .
C34 is a representative C-HR-derived peptide that inhibits HIV-1 fusion to host cells. It contains four key amino acids, W117, W120, D121 and I124, collectively designated as the N-terminal tryptophan-rich domain (N-TRD), which dock into a hydrophobic pocket (termed the 'deep pocket') formed by the N-HR trimer ( Figure 1B ) [4] . Enfuvirtide (T-20), which lacks 10 amino acids in the N-terminus that are present in C34, also contains four key amino acids, W159, N160, W161 and F162, which are collectively designated as the C-terminal tryptophan-rich domain (C-TRD). Both TRDs have been demonstrated to be important for inhibition of HIV-1 fusion [5] [6] [7] [8] [9] [10] . In a previous study, we used enzyme linked immunosorbent assay Introduction (ELISA) to demonstrate that T-20 binds weakly to the N-HR, even in the case of N-HR containing the entire T-20 binding region with amino acid positions from 18 to 73, whereas C34 binds strongly [11] . Our previous findings are consistent with other observations that T-20 may only transiently interact with N-HR and, instead, it inhibits HIV-1 fusion by targeting multiple sites in both gp120 and gp41 [12] . However, T20 has been shown to interact with an artificial 5-helix complex comprised of a linker-connected structure containing three N-HRs and two C-HRs, although the interaction was much weaker than that between C34 and the complex [13] . Hence, the C-TRD of T-20 may have a distinct role during the inhibition of HIV-1 fusion, other than binding to the N-HR. A mechanism that involves membrane association of T-20 via C-TRD has been previously proposed for the fusion inhibition [9, 12, 14] .
In contrast to the results from extensive biochemical analyses, the results accumulated from virological experiments support the hypothesis that T-20 interacts with the N-HR region. Hence, the majority of T-20-resistant HIV-1 variants acquire mutations in the N-HR, especially from L33 to L45, which is the putative interactive site of T-20 ( Figure 1B ) [15] [16] [17] [18] [19] [20] [21] [22] [23] . Moreover, the inhibitory effect of T-20 seems to depend on the specific sequence of the N-HR [24] .
Therefore, the avidity of T-20 for N-HR remains unclear. We hypothesized that any potential interactions of T-20 with N-HR-derived peptides would attenuate its anti-HIV-1 activity by adsorption into the added N-HR-derived peptides, which form an inactive 6-helix bundle. In this study, using synthesized various N-HRderived peptides with or without the putative T-20 binding region, we determined the anti-HIV-1 activity of T-20 and C34 in the presence of the synthesized peptides. Our data identify additive combinations of T-20 and N-HR-derived peptides, which may be valuable for treating HIV-1.
Methods

Cells and viruses
293T cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM l-glutamine, 100 U/ml penicillin, and 50 µg/ml streptomycin. HeLa-CD4/CCR5-LTR/βgal cells [25] ( 
Determination of drug susceptibility
Anti-HIV activity of inhibitors was determined using multinuclear activation of a galactosidase indicator (MAGI) assay as described previously [19, 24, [26] [27] [28] [29] [30] .
Briefly, HeLa-CD4-LTR-β-gal cells were inoculated with HIV-1 NL4-3 (60 MAGI units, generating 60 blue cells after 48 h of incubation) and cultured in the presence of various concentrations of peptides; 48 h after initial viral exposure, we counted all the blue cells that were stained with X-Gal (5-bromo-4-chloro-3-indolylβ-D-galactopyranoside). We assessed the antiviral activity of peptides based on the effective concentration that blocked HIV-1 infection by 50% (EC 50 ).
Statistical analysis
Dunnett's multiple comparisons test was used to evaluate whether the EC 50 values of T-20 were influenced in the presence of N-HR peptides. P-values <0.01 were considered statistically significant.
Results
Antiviral activity of the N-HR-derived peptides
Six N-HR-derived peptides, N36, N36-T, N46, N43-T, N45-T and N54, were synthesized with standard Fmocbased solid-phase techniques ( Figure 1B ) [31] . We first examined whether these N-HR-derived peptides exerted anti-HIV-1 activity with the MAGI assay [28] . We found that N36, N46 and N54, which include the entire deep pocket-forming region corresponding to N-TRD, were more active than N36-T, N43-T and N45-T, which include only part of the region ( Figure 1B) . However, addition of the region of N-HR that is believed to interact with C-TRD to the N-HR derived peptides had little influence on the activity of the N-HR-derived peptides. These results suggest that the addition of a deep pocket-forming region to N-HR-derived peptides provides enhanced antiviral activity of the peptides.
Combination of T20 and N-HR-derived peptides with a deep pocket-forming region
We also tested whether the anti-HIV-1 activity of T20 is attenuated when used in combination with the N-HR-derived peptides (Figure 2 ). Specifically, we examined the antiviral activity of T-20 or C34 at concentrations ranging from 0.1 to 100 nM, in the presence or absence of each N-HR-derived peptide (concentration at 30-40% inhibition of HIV replication), which provided the apparent effect of the combination among other concentrations tested. We found an additive effect in combination of T-20 and N36, N36-T or N46, which lack the interactive site for C-TRD in T-20 (Figure 2A) . By contrast, the activity of C34 was decreased to the level of C34 alone in the presence of N36, N36T or N46, respectively, which contains the N-TRD corresponding region ( Figure 2C ). Moreover, C34-mediated inhibition of the fusion was attenuated especially by N46 and N54 at 10 nM C34 (P<0.01; Figure 2C and 2D), indicating that a deep pocket region is important for a reduction in the C34 activity, possibly by a direct interaction (adsorption) with N-HR. Although N36-T and N46 include part of the C-TRD binding region, the avidity of the T-20 complex with these peptides seemed to be vulnerable in the fusion between HIV-1 and the host cells. Therefore, we further examined the N-HR-derived peptides that contain an entire interactive region of the C-TRD.
Role of C-TRD corresponding region in the N-HRderived peptides
The combination studies of T-20 revealed that the antiviral activity of N43-T or N45-T, but not of N54, which includes both the N-and C-TRD corresponding regions, was reduced to levels comparable to T-20 alone, indicating antagonism ( Figures 1B and 2B) . However, the antiviral activity of C34 was significantly antagonized by either N46 or N54 at 10 nM ( Figure 2C and 2D). These results indicate that putative interactive region in the N-HR-derived peptides for C-TRD plays small role in T-20 binding.
Discussion
In this study, we address possible combination of T-20 with the N-HR-derived peptides through their influence on T-20 activity. To date, the mechanisms of T-20 action have been extensively examined in protein-protein in vitro binding but rarely in actual HIV-1 entry. Previously, Liu et al. [12] also tried to reveal a role of the C-TRD in T-20 activity by T20-ANAA, which is like traditional T-20 but with a substitution from WNWF to ANAA in the C-TRD. T20-ANAA exhibited 450fold less anti-HIV-1 activity than T-20. However, it was shown that the moderate levels of T20-ANAA avidities toward N36-F10 [12] and the 5-helix bundle [13] were maintained, suggesting that the WNWF motif is unnecessary for binding to N-HR, but is important for potent anti-HIV-1 activity of T-20. Indeed, the overall reduction in T-20 activity by the N-HR peptides with the C-TRD corresponding region was moderate. The anti-HIV-1 activity of T-20 was not blocked by combination with N54, which includes both the C-TRD binding region and the deep pocket-forming region. The latter region may enhance the activity of the N-HR peptides and restore the antagonistic effect on T-20. We clearly demonstrated that unlike the C-TRD, which only weakly interacts with the N-HR, N-TRD, is definitively required for the interaction with the N-HR, thus playing a distinct role in HIV-1 fusion. Recently, it was reported that an N-HR-derived peptide lacking a binding site for the TRD of T-20, (CCIZN17) 3 , which is covalently stabilized by three interchain disulfides, can be effectively combined with T-20 [32] . To design sustained anti-HIV-1 activity of N-HR-derived peptides in combination with T-20, the amino acid sequence at positions 60-70 that forms a deep pocket should be included in the peptide and the N-terminal sequence of N-HR should be excluded. Our observations should be useful for further development of potent and N-HR-derived peptides that could be effectively combined with T-20. by National Institutes of Health grants AI076119, AI087489, AI074389 and AI079801.
